These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1415832)

  • 1. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.
    Renshaw PF; Guimaraes AR; Fava M; Rosenbaum JF; Pearlman JD; Flood JG; Puopolo PR; Clancy K; Gonzalez RG
    Am J Psychiatry; 1992 Nov; 149(11):1592-4. PubMed ID: 1415832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.
    Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Michelson D; Hornig-Rohan M; Beasley CM
    Am J Psychiatry; 1997 Jul; 154(7):963-9. PubMed ID: 9210747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation.
    Pato MT; Murphy DL; DeVane CL
    J Clin Psychopharmacol; 1991 Jun; 11(3):224-5. PubMed ID: 1741813
    [No Abstract]   [Full Text] [Related]  

  • 5. Human brain fluoxetine concentrations.
    Karson CN; Newton JE; Livingston R; Jolly JB; Cooper TB; Sprigg J; Komoroski RA
    J Neuropsychiatry Clin Neurosci; 1993; 5(3):322-9. PubMed ID: 8369643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation.
    Keck PE; McElroy SL
    J Clin Psychiatry; 1992 Apr; 53(4):127-9. PubMed ID: 1564047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.
    Strauss WL; Layton ME; Hayes CE; Dager SR
    Am J Psychiatry; 1997 Apr; 154(4):516-22. PubMed ID: 9090339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum fluoxetine and norfluoxetine concentrations and antidepressant response.
    Kelly MW; Perry PJ; Holstad SG; Garvey MJ
    Ther Drug Monit; 1989; 11(2):165-70. PubMed ID: 2785723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
    Strauss WL; Unis AS; Cowan C; Dawson G; Dager SR
    Am J Psychiatry; 2002 May; 159(5):755-60. PubMed ID: 11986128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study.
    Henry ME; Moore CM; Kaufman MJ; Michelson D; Schmidt ME; Stoddard E; Vuckevic AJ; Berreira PJ; Cohen BM; Renshaw PF
    Am J Psychiatry; 2000 Sep; 157(9):1506-8. PubMed ID: 10964871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain.
    Komoroski RA; Newton JE; Cardwell D; Sprigg J; Pearce J; Karson CN
    Magn Reson Med; 1994 Feb; 31(2):204-11. PubMed ID: 8133756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine and norfluoxetine.
    Mattes JA
    Am J Psychiatry; 1998 Nov; 155(11):1637. PubMed ID: 9812147
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine.
    Norman TR; Gupta RK; Burrows GD; Parker G; Judd FK
    Int Clin Psychopharmacol; 1993; 8(1):25-9. PubMed ID: 8473717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of fluoxetine in the clinical treatment setting.
    Lundmark J; Reis M; Bengtsson F
    Ther Drug Monit; 2001 Apr; 23(2):139-47. PubMed ID: 11294514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
    Bolo NR; Hodé Y; Nédélec JF; Lainé E; Wagner G; Macher JP
    Neuropsychopharmacology; 2000 Oct; 23(4):428-38. PubMed ID: 10989270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT.
    Tyrer SP; Marshall EF; Griffiths HW
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):797-805. PubMed ID: 1963498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
    Grady TA; Pigott TA; L'Heureux F; Hill JL; Bernstein SE; Murphy DL
    Am J Psychiatry; 1993 May; 150(5):819-21. PubMed ID: 8480832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder.
    Alessi N; Bos T
    Am J Psychiatry; 1991 Nov; 148(11):1605-6. PubMed ID: 1928487
    [No Abstract]   [Full Text] [Related]  

  • 19. Open trial of fluoxetine in obsessive-compulsive disorder.
    Jenike MA; Buttolph L; Baer L; Ricciardi J; Holland A
    Am J Psychiatry; 1989 Jul; 146(7):909-11. PubMed ID: 2787123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obsessive compulsive disorder, depression, and fluoxetine.
    Hollander E; Mullen L; DeCaria CM; Skodol A; Schneier FR; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1991 Oct; 52(10):418-22. PubMed ID: 1938978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.